Who Exports Melphalan from India — 153 Suppliers Behind a $12.8M Market

Hyderabad, often referred to as the "Bulk Drug Capital of India," contributes over 40% of the country's bulk drug production. The city hosts numerous manufacturers specializing in Active Pharmaceutical Ingredients (APIs) and bulk drugs. For instance, SVK Laboratories, established in 2007, focuses on producing high-quality APIs and intermediates, adhering to Good Manufacturing Practices (GMP) and ISO 9001:2015 standards. Similarly, Vasudha Pharma Chem Ltd., located in Jeedimetla, Hyderabad, is known for its bulk drug and intermediate manufacturing capabilities. This concentration of bulk drug manufacturers makes Hyderabad a pivotal hub for sourcing raw materials essential for pharmaceutical formulations.

The Ahmedabad-Vadodara corridor in Gujarat is renowned for its focus on pharmaceutical formulations. This region hosts a significant number of companies specializing in the production of finished dosage forms, including tablets, capsules, and injectables. For example, Alembic Pharmaceuticals, headquartered in Vadodara, manufactures and markets a wide range of pharmaceutical products, including APIs and formulations, with a presence in various therapeutic areas. Additionally, Schwitz Biotech in Ahmedabad engages in formulating, manufacturing, and exporting a diverse range of pharmaceutical formulations, adhering to FDA, WHO, GMP, and ISO 9002 quality standards. This specialization positions the Ahmedabad-Vadodara cluster as a key player in the production and export of pharmaceutical formulations.

The Mumbai-Thane-Raigad region serves as a critical export gateway for India's pharmaceutical industry. Its strategic coastal location facilitates efficient international shipping, making it a preferred base for pharmaceutical companies targeting global markets. The region's well-established infrastructure supports the export of both bulk drugs and finished formulations, enhancing India's position in the global pharmaceutical supply chain.

The Baddi-Nalagarh region in Himachal Pradesh has emerged as a significant pharmaceutical manufacturing hub, largely due to favorable tax incentives offered by the government. These incentives have attracted numerous pharmaceutical companies to set up manufacturing units in the area, contributing to its rapid industrial growth. The region's focus on cost-effective production makes it an attractive option for companies looking to optimize manufacturing expenses.

• Diversify Supplier Base: To mitigate risks associated with supply chain disruptions, consider sourcing APIs from multiple manufacturers across different clusters, such as Hyderabad for bulk drugs and Ahmedabad-Vadodara for formulations.

• Evaluate Export Capabilities: When targeting international markets, prioritize suppliers in the Mumbai-Thane-Raigad region due to their established export infrastructure and proximity to major ports.

• Leverage Cost Advantages: Explore manufacturing partnerships in the Baddi-Nalagarh region to benefit from tax incentives and cost-effective production facilities.

• Assess Quality Compliance: Ensure that all potential suppliers adhere to international quality standards, such as GMP and ISO certifications, to maintain product integrity and regulatory compliance.

By strategically engaging with these pharmaceutical clusters, companies can optimize their supply chains, enhance product quality, and effectively meet market demands for pharmaceuticals like Melphalan.